Hematology Xagena
Current available therapies for patients with acute myeloid leukemia ( AML ) who are ineligible for intensive therapy yield limited responses with poor survival. Venetoclax ( Venclyxto ) is a sele ...
Central nervous system ( CNS ) relapse of mantle cell lymphoma ( MCL ) is a rare phenomenon for which a standard of care has not been identified. Responses to conventional treatment for CNS-MCL are ...
Based on in vitro studies, Polatuzumab vedotin + Obinutuzumab + Venetoclax ( Pola-G-Ven )may have significant anti-tumor activity in relapsed / refractory follicular lymphoma ( R/R FL ). Researchers ...
Immunochemotherapy is standard of care for patients with previously untreated advanced stage follicular lymphoma ( FL ). Four-year data from the phase III GALLIUM study have previously demonstrated ...
Selinexor ( Xpovio ) is an oral, selective inhibitor of XPO1-mediated nuclear export, leading to the reactivation of tumor suppressor proteins. In a phase 1b/2 study, the combination of once weekl ...
The treatment of relapsed or refractory diffuse large B-cell lymphoma ( R/R DLBCL ) remains challenging. Atezolizumab ( Tecentriq ) and Obinutuzumab ( Gazyvaro ) are monoclonal antibodies acting res ...
Belantamab mafodotin, a B-cell maturation antigen targeting immunoconjugate, has demonstrated clinically meaningful, single-agent activity in patients with heavily pre-treated relapsed / refractory mu ...
Outcomes are poor in triple-class exposed patients with relapsed and refractory multiple myeloma ( RRMM ) who progress on immunomodulatory agents ( IMiDs ), proteasome inhibitors ( PIs ), and CD38 ant ...
JNJ-68284528 ( JNJ-4528 ) is a chimeric antigen receptor T ( CAR-T ) cell therapy containing 2 B-cell maturation antigen ( BCMA)-targeting single-domain antibodies. Researchers have presented updat ...
PD-1 blockade via Pembrolizumab ( Keytruda ) monotherapy has shown antitumor activity in relapsed or refractory classic Hodgkin lymphoma ( R/R cHL ). KEYNOTE-204 was a randomized, international, o ...
B2001X is a multicenter global study of Tisagenlecleucel ( Tisa-cel; Kymriah ) to provide access to patients with relapsed / refractory ( r/r ) acute lymphoblastic leukemia ( ALL ) including prior ant ...
Acalabrutinib ( Calquence ) is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved for patients with chronic lymphocytic leukemia ( CLL ) including those with relap ...
T cells expressing anti-CD19 chimeric antigen receptors ( CARs ) can cause complete remissions of relapsed lymphoma. The first clinical trial of anti-CD19 CAR T cells was conducted to show respons ...
Immunochemotherapy is standard of care for patients with previously untreated advanced stage follicular lymphoma ( FL ). Four-year data from the phase III GALLIUM study have previously demonstrated ...
Ibrutinib ( Imbruvica ) has shown single-agent activity in relapse / refractory ( R/R ) primary central nervous system lymphoma ( PCNSL ), and the high dose Methotrexate ( HD-MTX ) has been the backbo ...
